Literature DB >> 15888345

Transgenic mouse models for the prevention of breast cancer.

Qiang Shen1, Powel H Brown.   

Abstract

Breast cancer prevention research has made remarkable progress in the past decade. Much of this progress has come from clinical trials. However, in the future to test the many promising agents that are now available, pre-clinical models of breast cancer are needed. Such models are now available. Useful models include rat and mouse models, particularly, the genetically engineered mice (GEM). Many transgenic mouse models have been generated by manipulating growth factors and their receptors, cell cycle regulators, signal transduction pathways, cellular differentiation, oncogenes and tumor suppressor genes. The transgenes are induced to express in the mouse mammary glands under the control of various transgenic promoters, which have respective characteristics in expression pattern and other biological attributes. These models are providing invaluable insight on the molecular mechanisms of breast tumorigenesis. In this review, we discuss the relative relevance of the most commonly used transgenic mouse models for breast cancer prevention studies, and provide examples of how these transgenic models can be used to conduct cancer prevention research. Due to the multi-factor, multi-step nature of breast cancer, many factors should be incorporated into a valid prevention study. However, many barriers to progress must be overcome, including access to and availability of new cancer preventive drugs, and difficulties in conducting studies of combinations of preventive agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888345     DOI: 10.1016/j.mrfmmm.2004.10.013

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  9 in total

1.  Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland.

Authors:  Sonja E Volker; Shannon E Hedrick; Yvonne B Feeney; Charles V Clevenger
Journal:  Cancer Res       Date:  2018-06-29       Impact factor: 12.701

Review 2.  Pregnancy-induced changes in breast cancer risk.

Authors:  Irma H Russo; Jose Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-09       Impact factor: 2.673

3.  Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma.

Authors:  S Andò; R Malivindi; S Catalano; P Rizza; I Barone; S Panza; D Rovito; C Emprou; J-M Bornert; G Laverny; D Metzger
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

4.  Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

Authors:  Martín C Abba; Yuhui Hu; Carla C Levy; Sally Gaddis; Frances S Kittrell; Jamal Hill; Reid P Bissonnette; Powel H Brown; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

Review 5.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 6.  Breast cancer progression: insights into multifaceted matrix metalloproteinases.

Authors:  Vincent Chabottaux; Agnès Noel
Journal:  Clin Exp Metastasis       Date:  2007-10-30       Impact factor: 5.150

7.  Effects of limiting energy availability via diet and physical activity on mammalian target of rapamycin-related signaling in rat mammary carcinomas.

Authors:  Weiqin Jiang; Zongjian Zhu; Henry J Thompson
Journal:  Carcinogenesis       Date:  2012-11-03       Impact factor: 4.944

Review 8.  Extracellular proteolysis in transgenic mouse models of breast cancer.

Authors:  Kasper Almholt; Kirsty Anne Green; Anna Juncker-Jensen; Boye Schnack Nielsen; Leif Røge Lund; John Rømer
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

9.  Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models.

Authors:  Martin C Abba; Yuhui Hu; Carla C Levy; Sally Gaddis; Frances S Kittrell; Yun Zhang; Jamal Hill; Reid P Bissonnette; Daniel Medina; Powel H Brown; C M Aldaz
Journal:  BMC Med Genomics       Date:  2008-09-11       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.